Thus, anemia is one of the main side effects of anti-CD47 therapy observed in 89% of patients in a phase 1 trial of magrolimab in patients with acute myelocytic leukemia (AML) [28,29]. This evidence concerns the gene CD47 and anemia (phenotype).